SEC Company Response from ELITE PHARMACEUTICALS (ELTP) — Apr 14, 2009
ELITE PHARMACEUTICALS INC /NV/ (ELTP) (CIK 0001053369)
Date: April 14, 2009 · CIK: 0001053369 · Accession: 0000930413-09-002022
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-15697
Letter
Securities and Exchange Commission Division of Corporation Finance Re: Elite Pharmaceuticals, Inc. Item 4.01 - Form 8-K/A, filed March 12, 2009 File No. 001-15697
Dear Ms. Parikh:
On behalf of Elite Pharmaceuticals, Inc., a Delaware corporation (the “Company”), please be advised that the undersigned has received and read your letter, dated March 16, 2009, with regard to Item 4.01 of the Current Report on Form 8-K/A filed by the Company with the United States Securities and Exchange Commission (the “Commission”) on March 12, 2009.
The Company hereby acknowledges that:
•
the Company is responsible for the adequacy and accuracy of the disclosure in the filing;
•
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
•
the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Of course, if you should require any additional information or clarification, please do not hesitate to contact the undersigned at (201) 367-7860.
Securities and Exchange Commission
April 14, 2009
Re: Elite Pharmaceuticals, Inc.
Page 2 of 2
Your assistance in this matter is greatly appreciated.
Sincerely,
ELITE PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Elite Pharmaceuticals, Inc.
165 Ludlow Avenue
Northvale, NJ 07647
Tel: (201) 750-2646
April 14, 2009
AS FILED ON EDGAR AND
VIA FACSIMILE
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E., Mail Stop 6010
Washington, DC 20549
Attn: Sasha Singh Parikh, Staff Accountant
Re:
Elite Pharmaceuticals, Inc.
Item
4.01 - Form 8-K/A, filed March 12, 2009
File
No. 001-15697
Dear Ms. Parikh:
On
behalf of Elite Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
please be advised that the undersigned has received and read your letter,
dated March 16, 2009, with regard to Item 4.01 of the Current Report on Form
8-K/A filed by the Company with the United States Securities and Exchange
Commission (the “Commission”) on March 12, 2009.
The Company hereby acknowledges that:
•
the Company is responsible for the adequacy and accuracy of the disclosure in the filing;
•
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
•
the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Of
course, if you should require any additional information or clarification,
please do not hesitate to contact the undersigned at (201) 367-7860.
Securities and Exchange Commission
April 14, 2009
Re: Elite Pharmaceuticals, Inc.
Page 2 of 2
Your assistance in this matter is greatly appreciated.
Sincerely,
ELITE PHARMACEUTICALS, INC.
By: /s/ Chris Dick
Name:
Chris Dick
Title:
Chief Operating Officer and
Acting Chief Executive Officer
cc: Mark Gittelman, Chief Financial Officer